Munos' scorched-earth scheme is radical, but he's fast gaining followers among a generation of entrepreneurial bioscientists fed up with the way the corporate world makes drugs.
The discussion went down at our first annual Forbes Healthcare Summit last week, and the critic, Bernard Munos of the Innothink Center for Biomedical Innovation, did not disappoint.